Nautilus Biotechnology (NAUT) EBT (2020 - 2021)

Nautilus Biotechnology's (NAUT) quarterly EBT came in at -$1.8 million in Q1 2021, down 209.01% quarter-over-quarter from -$576035.0 in Q4 2020.

Nautilus Biotechnology (NAUT) EBT (2020 - 2021) Analysis & Trends

Nautilus Biotechnology has disclosed EBT across 2 years of filings, most recently posting -$1.8 million for Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT (Qtr)
1	Alterity Therapeutics	788,338.31 Bn	788,338.28 Bn	-	-
2	Belite Bio	56,560.00 Bn	56,560.00 Bn	-	-26.94 Mn
3	Quantum Biopharma	17,329.30 Bn	17,329.30 Bn	-	-2.97 Mn
4	Legend Biotech	3,341.00 Bn	3,340.71 Bn	242.10 Mn	19.60 Mn
5	Akari Therapeutics	1,727.91 Bn	1,727.91 Bn	-	-15.31 Mn
6	Evaxion A	1,536.68 Bn	1,536.67 Bn	-	-3.18 Mn
7	Psyence Biomedical	238.34 Bn	238.33 Bn	-	-1.50 Mn
8	Vertex Pharmaceuticals	113.42 Bn	106.17 Bn	2.59 Bn	1.25 Bn
9	Abivax	95.45 Bn	95.45 Bn	-	-56.48 Mn
10	Nautilus Biotechnology	298.22 Mn	202.36 Mn	-	-

Download Data